Effects of One-Year Tofacitinib Therapy on Lipids and Adipokines in Association with Vascular Pathophysiology in Rheumatoid Arthritis

Background: Cardiovascular (CV) morbidity, mortality and metabolic syndrome are associated with rheumatoid arthritis (RA). A recent trial has suggested increased risk of major CV events (MACE) upon the Janus kinase (JAK) inhibitor tofacitinib compared with anti-tumor necrosis factor α (TNF-α) therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Czókolyová, Monika, Hamar, Attila, Pusztai, Anita, Tajti, Gábor, Végh, Edit, Pethő, Zsófia, Bodnár, Nóra, Horváth, Ágnes, Soós, Boglárka, Szamosi, Szilvia, Szentpéteri, Anita, Seres, Ildikó, Harangi, Mariann, Paragh, György, Kerekes, György, Bodoki, Levente, Domján, Andrea, Hodosi, Katalin, Seres, Tamás, Panyi, György, Szekanecz, Zoltán, Szűcs, Gabriella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599623/
https://www.ncbi.nlm.nih.gov/pubmed/36291691
http://dx.doi.org/10.3390/biom12101483

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599623/
https://www.ncbi.nlm.nih.gov/pubmed/36291691
http://dx.doi.org/10.3390/biom12101483

Ejemplares similares